Barth syndrome
Jump to navigation
Jump to search
Epidemiology
- rare, congenital disorder
- affects at least 50 families worldwide, but may be underdiagnosed
- affects boys
Pathology
- metabolic changes
- cardiomyopathy
- weakened immune system
- hypoglycemia
Genetics
Clinical manifestations
- motor delays
- hypotonia
- delayed growth
- chronic fatigue
- lack of stamina
- mouth ulcers
- diarrhea
- physical & learning disability
Laboratory
Management
- elamipretide investigational
- bacterial infections in the context of neutropenia can be effectively treated with antibiotics
- granulocyte colony stimulating factor (G-CSF) is useful
- treat cardiomyopathy if indicated
- dietary supplementation with carnitine helps some, but in others has resulted in increasing muscle weakness & has precipitated heart failure
Prognosis:
- infections & heart failure are common causes of death
More general terms
References
- ↑ Lou N Elamipretide for Barth Syndrome Survives FDA Advisory Vote. Panelists acknowledge difficulty generating stronger data in ultra-rare disease. MedPage Today October 11, 2024 https://www.medpagetoday.com/publichealthpolicy/fdageneral/112353
- ↑ NINDS Barth Syndrome Information Page https://www.ninds.nih.gov/Disorders/All-Disorders/Barth-Syndrome-Information-Page